Background: Although plasma β-amyloid (Aβ) has been suggested to be a noninvasive diagnostic biomarker for Alzheimer’s disease (AD), its significance and validity have been inconclusive. Thus, it is quite important to establish a novel diagnostic method related to plasma Aβ. Methods: As our previous animal studies demonstrated a relation of glucose with plasma Aβ, we examined the effect of glucose loading on plasma Aβ levels in AD patients. After fasting, an oral glucose load was administered to AD patients and non-AD dementia patients, and subsequently, blood glucose, plasma insulin, and plasma Aβ levels were measured. Results: The plasma levels of baseline blood glucose, plasma insulin, and plasma Aβ were not different between the two groups. However, immediately after glucose loading, a significant increase in plasma Aβ40 and Aβ42 levels was observed in AD patients, whereas a mild decrease in plasma Aβ40 and Aβ42 levels was detected in non-AD dementia patients. Conclusion: The present study clearly demonstrated a different response in plasma Aβ40 and Aβ42 levels after glucose loading between AD and non-AD dementia patients, which is consistent with our previous animal studies. These findings suggest a novel diagnostic tool for AD using the elevation of plasma Aβ level after glucose loading, although further studies are necessary.

Keywords:
Diagnosis, Alzheimer’s disease, β-Amyloid, Glucose metabolism, Biomarker, Dementia screening
1.
Glenner GG, Wong CW: Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984;120:885–890.
2.
Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, et al: Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999;286:735–741.
3.
De Strooper B: Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron 2003;38:9–12.
4.
Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002;297:353–356.
5.
Wolfe MS: Inhibition and modulation of gamma-secretase for Alzheimer’s disease. Neurotherapeutics 2008;5:391–398.
6.
Nitsch RM, Hock C: Targeting beta-amyloid pathology in Alzheimer’s disease with Abeta immunotherapy. Neurotherapeutics 2008;5:415–420.
7.
Andreasen N, Blennow K: Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer’s disease. Peptides 2002;23:1205–1214.
8.
Jensen M, Schroder J, Blomberg M, Engvall B, Pantel J, Ida N, Basun H, Wahlund LO, Werle E, Jauss M, et al: Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer’s disease and declines with disease progression. Ann Neurol 1999;45:504–511.
9.
Takeda S, Sato N, Rakugi H, Morishita R: Plasma beta-amyloid as potential biomarker of Alzheimer disease: possibility of diagnostic tool for Alzheimer disease. Mol Biosyst 2010;6:1760–1766.
10.
Oh ES, Troncoso JC, Fangmark Tucker SM: Maximizing the potential of plasma amyloid-beta as a diagnostic biomarker for Alzheimer’s disease. Neuromolecular Med 2008;10:195–207.
11.
Kosaka T, Imagawa M, Seki K, Arai H, Sasaki H, Tsuji S, Asami-Odaka A, Fukushima T, Imai K, Iwatsubo T: The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43). Neurology 1997;48:741–745.
12.
Mann DM, Iwatsubo T, Cairns NJ, Lantos PL, Nochlin D, Sumi SM, Bird TD, Poorkaj P, Hardy J, Hutton M, et al: Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer’s disease: predominance of Abeta42(43). Ann Neurol 1996;40:149–156.
13.
Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, et al: Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med 1996;2:864–870.
14.
Iwatsubo T: Amyloid beta protein in plasma as a diagnostic marker for Alzheimer’s disease. Neurobiol Aging 1998;19:161–163.
15.
Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC: Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 2003;60:958–964.
16.
Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM: Plasma and cerebrospinal fluid levels of amyloid beta proteins 1–40 and 1–42 in Alzheimer disease. Arch Neurol 2000;57:100–105.
17.
Tamaoka A, Fukushima T, Sawamura N, Ishikawa K, Oguni E, Komatsuzaki Y, Shoji S: Amyloid beta protein in plasma from patients with sporadic Alzheimer’s disease. J Neurol Sci 1996;141:65–68.
18.
Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E: Standardization of measurement of beta-amyloid(1–42) in cerebrospinal fluid and plasma. Amyloid 2000;7:245–258.
19.
Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG: Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 2007;64:354–362.
20.
Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, Mehta PD: Plasma A[beta]40 and A[beta]42 and Alzheimer’s disease: relation to age, mortality, and risk. Neurology 2003;61:1185–1190.
21.
Schupf N, Tang MX, Fukuyama H, Manly J, Andrews H, Mehta P, Ravetch J, Mayeux R: Peripheral Abeta subspecies as risk biomarkers of Alzheimer’s disease. Proc Natl Acad Sci USA 2008;105:14052–14057.
22.
Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, Kurinami H, Shinohara M, Rakugi H, Morishita R: Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci USA 2010;107:7036–7041.
23.
Neumann KF, Rojo L, Navarrete LP, Farias G, Reyes P, Maccioni RB: Insulin resistance and Alzheimer’s disease: molecular links & clinical implications. Curr Alzheimer Res 2008;5:438–447.
24.
Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM: Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999,53:1937–1942.
25.
Takeda S, Sato N, Rakugi H, Morishita R: Molecular mechanisms linking diabetes mellitus and Alzheimer disease: beta-amyloid peptide, insulin signaling, and neuronal function. Mol Biosyst 2011;7:1822–1827.
26.
Sato N, Takeda S, Uchio-Yamada K, Ueda H, Fujisawa T, Rakugi H, Morishita R: Role of insulin signaling in the interaction between Alzheimer disease and diabetes mellitus: a missing link to therapeutic potential. Curr Aging Sci 2011;4:118–127.
27.
Cheng D, Noble J, Tang MX, Schupf N, Mayeux R, Luchsinger JA: Type 2 diabetes and late-onset Alzheimer’s disease. Dement Geriatr Cogn Disord 2011;31:424–430.
28.
Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P, Xu H: Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci 2001;21:2561–2570.
29.
Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ: Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 1998;273:32730–32738.
30.
Qiu WQ, Folstein MF: Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer’s disease: review and hypothesis. Neurobiol Aging 2006;27:190–198.
31.
Watson GS, Peskind ER, Asthana S, Purganan K, Wait C, Chapman D, Schwartz MW, Plymate S, Craft S: Insulin increases CSF Abeta42 levels in normal older adults. Neurology 2003;60:1899–1903.
32.
Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, Kurinami H, Shinohara M, Rakugi H, Morishita R: Elevation of plasma beta-amyloid level by glucose loading in Alzheimer mouse models. Biochem Biophys Res Commun 2009;385:193–197.
33.
Yaffe K, Weston A, Graff-Radford NR, Satterfield S, Simonsick EM, Younkin SG, Younkin LH, Kuller L, Ayonayon HN, Ding J, et al: Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 2011;305:261–266.
34.
Kulstad JJ, Green PS, Cook DG, Watson GS, Reger MA, Baker LD, Plymate SR, Asthana S, Rhoads K, Mehta PD, et al: Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease. Neurology 2006;66:1506–1510.
35.
Roher AE, Esh CL, Kokjohn TA, Castano EM, Van Vickle GD, Kalback WM, Patton RL, Luehrs DC, Daugs ID, Kuo YM, et al: Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer’s disease. Alzheimers Dement 2009;5:18–29.
36.
Chen M, Inestrosa NC, Ross GS, Fernandez HL: Platelets are the primary source of amyloid beta-peptide in human blood. Biochem Biophys Res Commun 1995;213:96–103.
37.
Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P, Xu H: Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci 2001;21:2561–2570.
38.
Qiu WQ, Folstein MF: Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer’s disease: review and hypothesis. Neurobiol Aging 2006;27:190–198.
39.
Craft S, Zallen G, Baker LD: Glucose and memory in mild senile dementia of the Alzheimer type. J Clin Exp Neuropsychol 1992;14:253–267.
40.
Fujisawa Y, Sasaki K, Akiyama K: Increased insulin levels after OGTT load in peripheral blood and cerebrospinal fluid of patients with dementia of Alzheimer type. Biol Psychiatry 1991;30:1219–1228.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.